Page 367 - Read Online

Page 12 of 15 Gururangan et al. Neuroimmunol Neuroinflammation 2018;5:45 I http://dx.doi.org/10.20517/2347-8659.2018.44

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Centers for Disease Control and Prevention. Declines in cancer death rates among children and adolescents in the United States, 1999–
2014. Available from: https://www.cdc.gov/nchs/products/databriefs/db257.htm. [Last accessed on 23 Oct 2018]
2. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, et al. CBTRUS statistical report: primary brain and other central
nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 2017;19:v1-88.
3. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nat Rev Cancer 2008;8:299-308.
4. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977;25:1-54.
5. Jackson CM, Lim M, Drake CG. Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res 2014;20:3651-9.
6. Graus F, Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol 2012;25:795-801.
7. Vivier E, Malissen B. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Immunol 2005;6:17-21.
8. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000;343:338-44.
9. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004;5:971-4.
10. Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013;25:396-402.
11. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77.
12. Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol 2007;8:1041-8.
13. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation. Adv Exp Med Biol 1997;417:1-6.
14. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand.
Blood 2000;96:878-84.
15. Shastri N, Cardinaud S, Schwab SR, Serwold T, Kunisawa J. All the peptides that fit: the beginning, the middle, and the end of the MHC
class I antigen-processing pathway. Immunol Rev 2005;207:31-41.
16. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-73.
17. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
18. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
19. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003;3:939-51.
20. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T
lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
21. Shahinian A, Pfeffer K, Lee KP, Kündig TM, Kishihara K, et al. Differential T cell costimulatory requirements in CD28-deficient mice.
Science 1993;261:609-12.
22. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011;11:852-63.
23. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, et al. Consensus nomenclature for CD8+ T cell phenotypes in cancer.
Oncoimmunology 2015;4:e998538.
24. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer
agents. Cancer Cell 2015;28:690-714.
25. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of
established tumors. Cancer Res 2011;71:4809-20.
26. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol
2002;2:251-62.
27. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-24.
28. Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH, et al. Overview of methodologies for T-cell receptor repertoire analysis.
BMC Biotechnol 2017;17:61.
29. Mack SC, Northcott PA. Genomic analysis of childhood brain tumors: methods for genome-wide discovery and precision medicine
become mainstream. J Clin Oncol 2017;35:2346-54.
30. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, et al. Immune checkpoint inhibition for hypermutant glioblastoma
multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016;34:2206-11.
31. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, et al. The landscape of genomic alterations across childhood
cancers. Nature 2018;555:321-7.
32. Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, et al. Molecular, pathological, radiological, and immune profiling of non-
brainstem pediatric high-grade glioma from the HERBY phase II randomized trial. Cancer Cell 2018;33:829-42.
33. Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence
of distinct immunological microenvironments that reflect tumor biology. J Neurosurg 2011;115:505-11.